Accessibility Menu
 

Tectonic Therapeutic

(NASDAQ) TECX

Current Price$30.48
Market Cap$576.82M
Since IPO (2024)+81%
5 Year-77%
1 Year+84%
1 Month-12%

Tectonic Therapeutic Financials at a Glance

Market Cap

$576.82M

Revenue (TTM)

$0.00

Net Income (TTM)

$74.15M

EPS (TTM)

$-4.04

P/E Ratio

-7.60

Dividend

$0.00

Beta (Volatility)

1.25 (Average)

Price

$30.48

Volume

3,312

Open

$30.56

Previous Close

$30.72

Daily Range

$29.92 - $31.31

52-Week Range

$14.38 - $36.03

TECX News

TECX: Motley Fool Moneyball Superscore

46

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tectonic Therapeutic

Industry

Biotechnology

Employees

60

CEO

Alise S. Reicin, MD

Headquarters

Watertown, MA 02472, US

TECX Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-38%

Return on Capital

-33%

Return on Assets

-28%

Earnings Yield

-13.16%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$576.82M

Shares Outstanding

18.78M

Volume

3.31K

Short Interest

0.00%

Avg. Volume

365.44K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$84.04M

EBITDA

$71.48M

Operating Cash Flow

$60.08M

Capital Expenditure

$208.00K

Free Cash Flow

$60.29M

Cash & ST Invst.

$253.80M

Total Debt

$1.28M

Tectonic Therapeutic Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$576.82M

N/A

Market Cap/Employee

$11.31M

N/A

Employees

51

N/A

Net Income

$19.23M

-55.4%

EBITDA

$18.27M

-54.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$252.52M

+83.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$43.00K

-91.7%

Short Term Debt

$1.23M

-55.7%

Return on Assets

-28.41%

N/A

Return on Invested Capital

-33.43%

N/A

Free Cash Flow

$14.49M

+13.9%

Operating Cash Flow

$14.46M

+14.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LYELLyell Immunopharma, Inc.
$24.12+7.73%
DBVTDBV Technologies S.A.
$21.75+5.63%
DRTSAlpha Tau Medical Ltd.
$7.70+5.62%
CLLSCellectis S.A.
$4.26+18.63%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.86+0.02%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$6.46+0.00%
MARAMara Holdings
$10.04+0.05%
IBITiShares Bitcoin Trust
$40.96-0.01%

Questions About TECX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.